Study of oral drug AUR108 for advanced lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests an experimental oral drug called AUR108 for people with advanced lymphoma that has come back after at least two prior treatments. The goal is to see if the drug is safe and if it can help shrink or control the lymphoma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have a type of lymphoma called non-Hodgkin or Hodgkin lymphoma that is stage III or IV.
- You must have already tried at least 2 different cancer treatments and they are no longer working.
- You must be able to swallow pills and have good enough liver, kidney, and blood counts as checked by your doctor.
- You cannot have lymphoma that started in the skin or untreated lymphoma in the brain or spinal cord.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new oral medication called AUR112 for people with advanced lymphoma or CLL that has not responded to at least 2 prior treatments. The goal is to see if it is safe and how it works in the body.
This early-phase study tests whether AUR107 is safe and may help shrink or control advanced solid tumors that have come back or progressed. You may be considered if standard treatments no longer work and you meet specific blood, organ, and health requirements.
This trial tests a new medication for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow their growth.
This trial tests a new drug, AWT020, for people with advanced cancer (solid tumors or lymphoma) that hasn't responded to other treatments. The goal is to see if it is safe and how well it works.
This early study tests a new medicine (JAB-2485) in adults with advanced solid tumors (cancers that have spread or grown locally). You may join to see if it can shrink tumors or control the disease when other treatments haven’t worked or weren’t tolerated.
This trial tests a new drug (AXT-1003) for people with advanced blood cancers (like non-Hodgkin lymphoma) or solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and how well it works.
Hear when a new Relapsed Advanced Lymphomas trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.